Human β-defensin 2 (hBD-2) improves neutrophilia and bacterial clearance during cigarette smoke exposure

Nadia Milad,Marie Pineault,Marie-Josée Beaulieu,Sophie Aubin,Benjamin AH Jensen,Mathieu Morissette
DOI: https://doi.org/10.4049/jimmunol.208.supp.50.09
2022-05-01
The Journal of Immunology
Abstract:Abstract Rationale Treatment of cigarette smoke-associated lung diseases has largely focused on broad-spectrum anti-inflammatory therapies, such as inhaled corticosteroids. However, these therapies have recently been shown to enhance patient susceptibility to pneumonia. Objective Assess whether the anti-microbial peptide, human β-defensin 2 (hBD-2), can simultaneously reduce pulmonary inflammation in cigarette smoke-exposed mice while maintaining immune competence during bacterial exacerbation. Methods Mice were exposed to cigarette smoke acutely (4 days) or chronically (5 days/week for 7 weeks) and administered hBD-2 intranasally or by gavage. In a separate model of acute exacerbation, chronically exposed mice treated with hBD-2 were infected with non-typeable Haemophilus influenzae prior to sacrifice. Results In the acute exposure model, cigarette smoke-associated pulmonary neutrophilia was significantly blunted by both local and systemic hBD-2 administration. Similarly, chronically exposed mice administered hBD-2 therapeutically exhibited reduced pulmonary neutrophil infiltration and downregulated pro-inflammatory signaling in the lungs compared to vehicle-treated mice, as assessed via microarray. Finally, in a model of bacterial exacerbation, hBD-2 administration effectively limited neutrophil infiltration in the lungs while markedly reducing pulmonary bacterial load. Conclusions This study shows that hBD-2 treatment can significantly attenuate lung neutrophilia induced by cigarette smoke exposure while preserving immune competence and promoting an appropriate host-defense response to bacterial stimuli. Supported by CIHR
immunology
What problem does this paper attempt to address?